Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice

• Main Authors: Yongchuan Gu (Author), Tony T.-A. Chang (Author), Jingli Wang (Author), Jagdish K. Jaiswal (Author), David Edwards (Author), Noel J. Downes (Author), H. D. Sarath Liyanage (Author), Courtney R. H. Lynch (Author), Frederik B. Pruijn (Author), Anthony J. R. Hickey (Author), Michael P. Hay (Author), William R. Wilson (Author), Kevin O. Hicks (Author)
• Format: Book
• Published: Frontiers Media S.A., 2017-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

3-(3-Morpholinopropyl)-7,8-dihydro-6H-indeno[5,6-e][1,2,4]triazine 1,4-dioxide (SN30- 000), an analog of the well-studied bioreductive prodrug tirapazamine (TPZ), has improved activity against hypoxic cells in tumor xenografts. However, little is known about its biotransformation in normal tissues....